CERAMENTTM|G and V in the Management of Hip and Knee Arthroplasty Revisions (Revision Arthroplasty Italy)
Open-label, multicentre, prospective cohort, observational clinical trial with a retrospective control group to evaluate the effectiveness and safety of CERAMENTTM| G or V used for filling of bone defects in the tibia and / or femur shaft and/or acetabulum in patients scheduled for two-stage hip or knee prosthesis re-implantation for PJI or aseptic loosening.
The results will be compared to a cohort of patients, which have been treated before the introduction of CERAMENTTM|G or V for the same indication.
Due to the observational character of the study, there will be no patient randomization and the clinicians in the study will remain entirely free to decide on the treatment of the patients according to established clinical practice.
Only patients for whom therapeutic strategy for the use of the product for filling bone defects is already planned according to local clinical practice, at the time of informed consent form signature, will be enrolled in this study. Thus, the decision for the choice of the surgical treatment, will not be influenced by the inclusion of the patient in this study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: CARLO L ROMANO, MD
- Phone Number: 907 +39026621441
- Email: carlo.romano@grupposandonato.it
Study Contact Backup
- Name: NICOLA LOGOLUSO, MD
- Phone Number: 903 +39026621441
- Email: nicola.logoluso@gmail.com
Study Locations
-
-
-
Milano, Italy
- Recruiting
- IRCCS Galeazzi
-
Contact:
- CARLO L ROMANO, MD
- Phone Number: 907 +39026621441
- Email: carlo.romano@grupposandonato.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained prior to any study related procedure.
- Male or female age ≥ 18 and ≤ 85 years.
- Patients diagnosed with aseptic prosthetic loosening and scheduled for a one-stage hip or knee cementless or hybrid revision prosthesis implantation
- Patients with an interval spacer and scheduled for hip or knee cementless or hybrid revision prosthesis implantation.
- For those patients with an interval spacer, previous infection caused by microorganism(s) sensitive to gentamicin or vancomycin.
- Able (in the Investigators opinion) and willing to comply with all study requirements
Exclusion Criteria:
- Unable to give written informed consent.
- Medically unfit for operative intervention.
- Soft-tissue defects that prevent direct skin closure at revision surgery.
- Females who are pregnant or lactating.
- Females of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions may be included.
- Known allergy to gentamicin or vancomycin (or related antibiotics).
- Patients with previous nephro- or ototoxicity events due to aminoglycoside and/or vancomycin (or glycopeptides) use.
- Presence of relevant contraindications as described in the EU CE mark Instructions for Use (IFU).
- Myasthenia gravis.
- Need of a fully cemented joint prosthesis.
- Psychiatric or neurological disorders.
Active infection at the site of surgery as diagnosed by clinical and/or laboratory and/or imaging investigations.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Treated with Device: Including sham
Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum.
|
During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum.
These bone defects are filled with CERAMENTTM|G or V during the re-implantation of the cementless or hybrid revision THA or TKA.
CERAMENTTM|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum.
Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM|G or V into the bone defects.
For information of handling and mixing please see the attached instructions for use (IFU).
|
|
No Intervention: Control
Control without CERAMENT device
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
incidence of post-surgical infection
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: CARLO L ROMANO, MD, IRCCS Galeazzi
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RAI2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hip Prosthesis Infection
-
NCT06605651Not yet recruitingHip Prosthesis Infection | Knee Prosthesis Infection
-
NCT04993027Not yet recruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint Prosthesis
-
NCT06402591Active, not recruitingSurgical Site Infection | Joint Infection | Infection, Surgical Site | Infection Prosthesis Hip and Knee | Infection, Prosthesis Related | Infection Pro
-
NCT03161990CompletedArthroplasty Complications | Hip Prosthesis Infection
-
NCT05369104RecruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint Prosthesis
-
NCT02660268CompletedHip Prosthesis Infection
-
NCT04119804Completed
-
NCT02842684CompletedInfection of Total Hip Joint Prosthesis
-
NCT05932823CompletedHip Prosthesis Infection
Clinical Trials on CERAMENT G V
-
NCT06628115Not yet recruitingOsteomyelitis - Foot
-
NCT02820363CompletedTibial Fracture
-
NCT06555848Recruiting
-
NCT06010433RecruitingDiabetic Foot Osteomyelitis | Chronic Osteomyelitis | Fracture Related Infection
-
NCT07057817Not yet recruitingDiabetes | Osteomyelitis | Calcanectomy
-
NCT04805164Recruiting
-
NCT00661024Completed